<DOC>
	<DOCNO>NCT01627561</DOCNO>
	<brief_summary>The current study evaluate immunogenicity safety Cervarix administer accord 2-dose schedule without co-administration GSK Biologicals ' MMR DTPa vaccines 4-6 year old female subject compare standard 3-dose schedule 15-25 year old female subject , population clinical efficacy demonstrate .</brief_summary>
	<brief_title>Safety Immunogenicity GSK Biologicals ' HPV-16/18 L1 VLP AS04 Vaccine ( GSK-580299 ) Healthy Female Children 4-6 Years Old</brief_title>
	<detailed_description>The study conduct partially blinded manner : - The study single-blind HPV_2D MMR_DTPa group Month 12 visit due difference visual appearance study vaccine . Between Month 12 study conclusion ( Month 36 ) , study open respect HPV_2D group . - The study open respect HPV_2D CO group subject group receive two vaccine co-administered scheduled vaccination visit . - The study open respect HPV_3D group subject group receive three injection .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] comply requirement protocol . A female , include , 4 6 year age time first vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject prior enrolment study . Healthy subject establish medical history clinical examination enter study . Subjects receive four dos DTP vaccine ( i.e. , three dos first year life fourth dose second year life ) accord schedule applicable participating country . Subjects receive first dose MMR vaccine accord schedule applicable participating country . Child care . Previous vaccination HPV plan administration another HPV vaccine study foreseen protocol . Planned administration/administration vaccine foreseen study protocol within 30 day first dose study vaccine ( ) . Administration routine meningococcal , hepatitis B , hepatitis A , inactivated influenza and/or poliomyelitis vaccine 8 day first dose study vaccine ( ) allow . Enrolment defer subject outside specify window . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine ( ) , plan use study period . History reaction hypersensitivity likely exacerbate component study vaccine , include latex and/or obvious allergic reaction neomycin ( history contact dermatitis neomycin contraindication ) , egg protein , etc . ( e.g . hive , swell mouth throat , difficulty breathing , hypotension , shock subsequent egg ingestion ) . Cancer autoimmune disease treatment . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Previous administration MPL AS04 adjuvant . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine ( ) plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Family history congenital hereditary immunodeficiency . Documented human immunodeficiency virus ( HIV ) positive subject . Major congenital defect serious chronic illness . History seizures serious neurological disorder , , accord judgment investigator , preclude administration study vaccine . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screening test , opinion investigator precludes administration study vaccine ( ) . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C oral , axillary tympanic setting , ≥ 38.0°C rectal setting . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may , enrol discretion investigator . Enrolment deferred condition resolve . Previous administration fifth dose DTP vaccine and/or second dose MMR vaccine plan administration DTP vaccine and/or MMR vaccine outside study ( study period Day 0 Month 12 ) . History tetanus , diphtheria , pertussis , measles , mumps and/or rubella . Known exposure diphtheria household exposure pertussis within 30 day prior vaccination DTPa . Known exposure measles , mumps and/or rubella 30 day prior vaccination MMR study vaccine . Confirmed suspect tuberculosis . Severe allergic reaction ( e.g . anaphylaxis severe Arthustype hypersensitivity reaction ) follow administration previous dose ( ) DTP MMR vaccine . Hyperpyrexia ( ≥ 40.5°C ) within 48 hour administration previous dos DTP MMR vaccine . Persistent , inconsolable cry last 3 hour , occur within 48 hour administration previous dos DTP vaccine . Collapse shockinglike state ( hypotonichyporesponsive episode ) within 48 hour administration previous dos DTP vaccine . Idiopathic thrombocytopenic purpura bleed disorder . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within six month prior first vaccine dose ( ) . ( For corticosteroid , mean prednisone ≥ 0.5 mg/kg/day , equivalent . Inhaled topical steroid allow . )</criteria>
	<gender>Female</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Immune response</keyword>
	<keyword>Human papillomavirus</keyword>
	<keyword>HPV vaccine</keyword>
	<keyword>Safety</keyword>
</DOC>